NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections.
The announcement comes amid growing concerns over the spread of hantaviruses, which can cause severe respiratory illness. The Andes hantavirus incident underscores the vulnerability of global health systems to novel viral outbreaks and the urgent need for treatments that are effective across multiple virus families. NanoViricides' NV-387, a unique broad-spectrum antiviral, has shown promise in animal models for monkeypox, smallpox, and measles, in addition to respiratory viruses. The drug candidate recently completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, positioning it for advancement into Phase II trials.
The company's focus on broad-spectrum antivirals is particularly relevant as the world continues to grapple with the COVID-19 pandemic and faces the possibility of future pandemics. NV-387's mechanism of action, which targets viral entry and replication, could provide a first line of defense against emerging pathogens. According to the company, NV-387 is effective in animal models for multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox, and measles, highlighting its potential as a platform technology.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections. The company also has another advanced drug candidate, NV-HHV-1, for the treatment of all herpesvirus infections, including HSV-1, HSV-2, VZV shingles, and chickenpox. However, the company cannot project an exact date for filing an IND for any of its drugs due to dependence on external collaborators and consultants.
Investors and stakeholders can stay updated on the latest news and developments from NanoViricides in the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/OYkof.
